Iovance Biotherapeutics, Inc. (IOVA)

Iovance Biotherapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 6, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	814	2,255	2,081	1,009	2,995	6,806
Market Cap Growth	-72.96%	8.40%	106.29%	-66.33%	-55.99%	94.85%
Enterprise Value	563	1,937	1,799	729	2,491	6,103
Last Close Price	1.81	7.40	8.13	6.39	19.09	46.40
PS Ratio	2.37	13.75	1749.89	-	-	-
PB Ratio	0.89	3.18	3.56	2.02	4.82	10.37
P/TBV Ratio	2.02	5.27	5.86	2.02	4.82	10.37
EV/Sales Ratio	2.25	11.81	1512.80	-	-	-
Debt / Equity Ratio	0.08	0.08	0.13	0.17	0.12	0.08
Asset Turnover	-	0.19	0.00	-	-	-
Inventory Turnover	-	4.01	-	-	-	-
Quick Ratio	-	3.21	2.54	5.16	5.66	11.47
Current Ratio	-	3.74	2.79	5.24	5.70	11.59
Return on Equity (ROE)	-	-57.48%	-81.91%	-70.61%	-53.55%	-54.34%
Return on Assets (ROA)	-	-29.22%	-39.86%	-34.59%	-27.71%	-29.42%
Return on Capital (ROIC)	-32.05%	-34.57%	-46.22%	-39.01%	-30.57%	-32.14%
Earnings Yield	-49.06%	-16.50%	-21.34%	-39.25%	-11.43%	-3.81%
FCF Yield	-	-16.14%	-18.46%	-31.05%	-8.87%	-3.70%
Buyback Yield / Dilution	-19.46%	-23.28%	-47.64%	-3.82%	-10.92%	-11.23%

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q